Amphotericin B lipid complex for the treatment of invasive fungal infections

Bibliography

• GROLL AH, SHAH PM, MENTZEL Cet al.: Trends in the postmortem epidemiology of invasive fungal infections at a university hospital.' Infect. (1996) 33:23–32.
   Google Scholar
• MCNEIL MM, NASH SL, HAJIEH RAet al.: Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin. Infect. Dis. (2001) 33:641–647.
   Google Scholar
• JARVIS WR: Epidemiology of nosocomialfungal infections with emphasis on Candida species. Clin. Infect. Dis. (1995) 20:1526–1530.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, JONES RN, MESSER SA et al.: National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program. Diag. Microbial Infect. Dis. (1998) 31:327–332.
   PubMed Web of Science ®Google Scholar
• WINGARD JR: Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin. Infect. Dis. (1995) 20:115–125.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, JONES RN, MESSER SA et al.: National surveillance of nosocomial blood stream infections due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn. Microbial. Infect. Dis. (1998) 30:121–129.
   PubMed Web of Science ®Google Scholar
• LIN SJ, SCHRANZ J, TEUTSCH SM: Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. (2001) 32:358–366.
   PubMed Web of Science ®Google Scholar
• HUSAIN S, ALEXANDER B, MUNOZ P et al.: Opportunistic mycelial fungal infections in organ transplant recipients: Emerging importance of non-Aspergillus mycelial fungi. Clin. Infect. Dis. (2003) (In Press).
   Google Scholar
• PATTERSON TF: Invasive mycoses: management and unmet needs. Curt: Opin. Infect. Dis. (2001) 14:669–671.
   PubMed Web of Science ®Google Scholar
• TERRELL CL: Antifungal agents. Pazt II. The azoles. Mayo Clin. Proc. (1999) 74:78–100.
   PubMed Web of Science ®Google Scholar
• PATEL R: Antifungal agents. Part I. Amphotericin B Preparations and Flucytosine. Mayo Clin. Proc. (1998) 73:1205–1225.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of the mechanisms of action, activity spectrum and toxicities of conventional amphotericin B.
   Google Scholar
• SABRA R, BRANCH RA: Amphotericin B nephrotoxicity. Drug Sal (1990) 5:94–108.
   PubMed Web of Science ®Google Scholar
• BATES DW, SU L, YU T et al: Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. (2001) 32:686–693.
   PubMed Web of Science ®Google Scholar
• •This study focuses on the incremental attributable mortality, morbidity and costs secondary to amphotericin B-related nephrotoxicity in a mixed group of immunocompromised and immunocompetent patients at an academic medical centre.
   Google Scholar
• WINGARD JR, KUBILIS P, LEE L et al: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.Gin. Infect. Dis. (1999) 29:1408–1410.
   PubMedGoogle Scholar
• WONG-BERINGER A, JACOBS RA, GUGLIELMO BJ: Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. (1998) 27:603–618.
   PubMed Web of Science ®Google Scholar
• BANGHAM AD, HILL MW,MILLER NGA: Preparations and uses of liposomes as models of biological membranes. Methods Mem& Biol. (1974) 1:1–68.
   Google Scholar
• MEHTA K, LOPEZ BERENSTEIN G, HERSH EM et al.: Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes. Reticuloendothelial Soc. (1982) 32:155–164.
   PubMedGoogle Scholar
• LOPEZ-BERENSTEIN G, MEHTA K, MEHTA R et al.: The activation of human monocytes by liposome-encapsulated muramyl-dipeptide analogues. Immunol (1983) 130:1500–1502.
   Google Scholar
• LOPEZ-BERENSTEIN G, HOPFER RI,MEHTA R et al.: Liposome-encapsulated amphotericin B for the treatment of disseminated candidiasis in neutropenic mice. Infect. Dis. (1984) 150:278–283.
   Google Scholar
• LOPEZ-BERENSTEIN G,FAINSTEIN V, HOPFER R et al.: Liposomal amphotericin B for the treatment of fungal infections in patients with cancer: a preliminary report. Infect. Dis. (1985) 151:704–710.
   Google Scholar
• •One of the first human clinical trials investigating the efficacy and toxicity of a lipid formulation of amphotericin B which was the forerunner to ABLC.
   Google Scholar
• LOPEZ-BERENSTEIN G, BODEY GP, FRANKEL LS et al.: Treatment of hepatosplenic candidiasis with liposomal amphotericin B. I Clin. Oncol (1987) 5:310–317.
   PubMedGoogle Scholar
• BRAJBURG J, POWDERLY WG, KOBAYASHI GS et al.: Amphotericin B: current understranding of mechanisms of action. Antimicrob. Agents Chemother: (1990) 34:183–188.
   PubMedGoogle Scholar
• SOKOL-ANDERSON ML, BRAJBURG J, MEDOFF G: Amphotericin B-induced oxidative damage and killing of Candida albicans. Infect. Dis. (1986) 154:76–83.
   Google Scholar
• JANOFF AS, PERKINS WR,SALETAN SL et al.: Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities. J. Liposome Res. (1993) 3:451–471.
   Google Scholar
• Enzon Pharmaceuticals: Abelcee' (Amphotericin B lipid complex) package insert. Enzon Pharmaceuticals.
   Google Scholar
• SPEELWWELD E, GORDTS B,VAN LANDUYT HW et al.: Susceptibility of clinical isolates of Fusarium to antifungal drugs. Mycoses (1996) 39:37–40.
   Google Scholar
• ORAVOCA E, MISTRIK M,SAKALOVA A et al.: Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients. Chemotherapy (1995) 41:473–78.
   Google Scholar
• STERLING T, GASSER RA, ZIEGLER A: Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immuncompetent host. Clin. Infect. Dis. (1996) 23:187–188.
   PubMedGoogle Scholar
• CROSS JT Jr, HICERSON SL, YAMAAUCHI T: Antifungal drugs. Pediatr. Rev (1995) 16:123–129.
   PubMedGoogle Scholar
• JESSUP C, REYES G, FOTHERGILL A et al.: A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphohtericin B: a multicenter study. Chemother: (2000) 12:22–29.
   Google Scholar
• CARRILLO-MUNOZ AJ, QUINDOS G, TUR C et al.: Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole. Chemotherapy (2000) 46:235–244.
   PubMed Web of Science ®Google Scholar
• SWENSON CJE, PERKINS WR, ROBERTS P et al: In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipase important? Antimicrob. Agents Chemother. (1998) 42:767–771.
   PubMedGoogle Scholar
• GOTTFREDSSON M, JESSUP CJ, COX GM et al.: Fungal phospholipase activity and susceptibility to lipid preparations of amphotericin B. Antimicrob. Agents Chemother: (2001) 45:3231–3233.
   PubMedGoogle Scholar
• CLARK JM, WHITNEY RR, OLSEN SJet al: Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob. Agents Chemother: (1991) 5:615–21.
   Google Scholar
• CLEMONS KV, STEVENS DA: Therapeutic efficacies of Amphotec, Ambisome and Abelcet against systemic murine cryptococcosis. In: Proceedings and Abstracts of the Focus on Fungal Infections, San Antonio, CA, USA (1997) (Abstract 23).
   Google Scholar
• CLEMONS KV, STEVENS DA: Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob. Agents Chemother. (1991) 35:2144–2146.
   PubMed Web of Science ®Google Scholar
• CLEMONS KV, STEVENS DA: Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis.J. Antimicrob. Chemother. (1992) 30:353–363.
   PubMed Web of Science ®Google Scholar
• KAN VL, BENNETT JE, AMANTEA MA et al: Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers.' Infect. Dis. (1991) 164:412–421.
   Google Scholar
• ADEDAYO A, BERNARDO JF, SWENSON CE et al.: Pharmacokinetic profile of ABELCET (Amphotericin B Lipid Complex Injection): combined experience from Phase I and Phase II studies. Antimicrob. Agents Chemother: (1997) 41:2201–2208.
   PubMedGoogle Scholar
• •A detailed investigation of ABLC pharmacokinetics in humans receiving ABLC for mycotic infection. This study emphasises the unique rapid uptake and tissue distributions of ABLC compared to conventional amphotericin B.
   Google Scholar
• POSTE G: Liposome taregeting in vivo: problems and opportunities. Biol. Cell (1983) 47:19–37.
   Web of Science ®Google Scholar
• JANOFF AS, BONI LT, POPESCU MC et al.: Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. USA (1988) 544:590–597.
   Google Scholar
• WASAN KM, LOPEZ-BERENSTEIN G: Characteristics of lipid-based formulationsthat influece their biologic behavior in the plasma of patients. Gin. Infect. Dis. (1996) 23:1126–1138.
   PubMed Web of Science ®Google Scholar
• MEHTA K, LOPEZ-BERENSTEIN G, HOPFER et al.: Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochem. Biophys. Acta (1984) 770:230–234.
   PubMed Web of Science ®Google Scholar
• OLSEN SJ, SWERDEL MR, BLUE B et al.: Tissue distribution of amphoteicin B lipid complex in laboratory animals. Pharm. Pharmacol (1991) 43:831–835.
   PubMed Web of Science ®Google Scholar
• RAMASWAMY M, PETEHERYCH KD, KENNEDY AL et al.: Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrob. Agents Chemother: (2001) 45:1184–1191.
   PubMed Web of Science ®Google Scholar
• WASAN KM, CONKLIN JS: Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low density lipoprotein cholesterol. Gin. Infect. Dis. (1997) 24:78–80.
   PubMed Web of Science ®Google Scholar
• KENNEDY AL, WASAN KM: Preferentialdistribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content. Pharm. Sci. (1999) 88:1149–1155.
   PubMedGoogle Scholar
• SULLIVAN GW, CARPER HT, MANDELL GL: Lipid complexing decreases amphotericin B inflammatory activation of human neutrophils compared with that of a desoxycholate-suspended preparation of amphohtericin B (Fungizone). Antimicrob. Agents Chemother: (1992) 36:39–45.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, HIEMENZ JW, SEIBEL NL et al.: Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. (1998) 26:1383–1396.
   PubMed Web of Science ®Google Scholar
• •The largest reported open-label series ABLC-treated mycotic infection in patients enrolled during an emergency use protocol due to refractory infection to- or intolerance of conventional antifungal therapy.
   Google Scholar
• LINDEN P, WILLIAMS P, CHAN KM: Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid organ transplant recipients with invasive fungal infection. Clin. Transplant. (2000) 14:329–339.
   PubMed Web of Science ®Google Scholar
• KLINE S, LARSEN A, FIEBER L et al.: Limited toxicity of prolonged therapy with high dose amphotericin B lipid complex. Gin. Infect. Dis. (1995) 21:1154–1158.
   PubMed Web of Science ®Google Scholar
• ANAISSIE EJ, WHITE M, UZUN 0 et al.: Amphotericin B lipid complex versus amphotericin B for treatment of invasive candidiasis: a prospective, randomized, multicenter trial In: Programs and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA (1995):330 (Abstract LM21).
   Google Scholar
• HIEMENZ JVV, LISTER J, ANAISSIE EJ et al.: Emergency use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical control comparision with amphotericin B. Blood (1995) 86\(Suppl. 1) 849a (Abstract 3283).
   Google Scholar
• LINDEN PK, COLEY K, FONTES P et al: Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin. Clin. Infect. Dis. (2003) 37:17–25.
   PubMed Web of Science ®Google Scholar
• •A retrospective study in liver transplant recipients demonstrating a significant survival benefit of first-line or early second line ABLC therapy in patients with definie or probable invasive aspergillosis compared to an historical control treated with conventional amphotericin B.
   Google Scholar
• SHARKEY PK, GRAYBILL JR,JOHNSON ES et al.: Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. (1996) 22:315–321.
   Google Scholar
• LINDEN P, LEE L, WALSH TJ: Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections. Pharmacotherapy (1999) 19:1261–1268.
   PubMed Web of Science ®Google Scholar
• MARTINO R, SUBIRA M,DOMINGO-ALBOS A et al.: Low dose amphotericin B lipid complex for the treatment of persistent fever of unknown origin in patients with hematologic malignancies and prolonged neutropenia. Chemotherapy (1999) 45:205–212.
   Google Scholar
• GONZALEZ CE, COURIEL DR, WALSH TJ: Disseminated zygomycosis in a neutropnic patient: successful treatment with amphotericin B lipid complex and granulocyte-colony stimulating factor. Gin. Infect. Dis. (1997) 24:192-196. 2108
   Google Scholar
• HUNSTAD DA, COHEN AH,ST GEME JW 3rd: Successful eradication of mucormycosis occurring in a pulmonary allograft. Heart Lung Transplant. (1999) 18:801–804.
   PubMed Web of Science ®Google Scholar
• WENG DE, WILSON WH, LITTLE R et al: Successful medical management of isolated renal zygomycosis: case report and review. Clin. Infect. Dis. (1998) 26:601–605.
   PubMed Web of Science ®Google Scholar
• KOEHLER AP, CHENG AFB, CHU KC et al: Successful treatment of disseminated coccidioidomycosis with amphotericin B lipid complex.J Infect. (1998) 36:113–115.
   PubMedGoogle Scholar
• MEYER MH, LESTSCHER V, WALLER J et al.: Chronic disseminated Trichosporion asahii infection in a leukemic child.Clin. Infect. Dis. (2002) 35:e22–e25.
   Google Scholar
• KANE SL, DASTA JF, COOK CH: Amphotericin B lipid complex for Hansenula anomala pneumonia. Ann. Pharmacother. (2002) 36:59–62.
   PubMedGoogle Scholar
• LUI AY, TURRETT GS, KARTER DL et al.: Amphotericin B lipid complex therapy in an AIDS patients with Rhodotorula rubra fungemia. Clin. Infect. Dis. (1998) 27:892–892.
   PubMedGoogle Scholar
• PATTERSON TS, BARTON LL, SHEHAB ZM et al.: Amphotericin B lipid complex treatment of a leukemic child with disseminated Fusarium solani infection. Clin. Pediatr. (1996) 35:257–260.
   PubMed Web of Science ®Google Scholar
• WINGARD JR, WHITE MH,ANAISSIE E et al: A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin. Infect. Dis. (2000) 31:1155–1163.
   PubMed Web of Science ®Google Scholar
• •A prospetive, blinded controlled trial comparing ABLC (5 mg/kg/day) to L-AmB (5 or 3 mg/kg/day) in an oncological population which demonstrated lower day 1 infusion toxicities, nephroxoticity and treatment discontinuation rates for L-AmB-treated patients but comparable efficacy rates.
   Google Scholar
• FLEMING V, KANTARJIAM HM, HUSNI R et al: Comparison of amphotericin B lipid complex (ABLC) versus ambisome in the treatment of suspected or documented fungal infection in patients with leukemia. Leak. Lymphoma (2001) 40:511–520.
   PubMed Web of Science ®Google Scholar
• •A prospective trial comparing ABLC versus L-AmB (3 mg/kg/day for fever of unknown origin-neutropenia and
   Google Scholar
• mg/kg/day for definite infection) whichdid not show significant differences in infusion- or nephrotoxicity but did show higher rates of hepatotoxicity and lower efficacy rates in the L-ArnB group.
   Google Scholar
• CANNON JP, GAREY KW,DANZIGER LH: A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy (2001) 21:1107–1114.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, SEIBEL N, ARNDT C et al.: Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatric Infect. Dis. J. (1999) 18:702–713.
   PubMed Web of Science ®Google Scholar
• HERBRECHT R, AUVRIGNON A, ANDRES E et al: Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Ear. I Clin. Microbiol Infect. Dis. (2001) 20:77–82.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, WHITCOMB P,PISCITELLI S et al.: Safety, tolerance and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob. Agents Chemother. (1997) 41:1944–1948.
   Google Scholar
• LINDEN P, KRAMER DJ, MAZARIEGOS G et al.: Low dose amphotericin B (LDA) for the prophylaxis of serious Candida infection in high-risk liver recipients. Proceedings of the 3ffh International Conference on Antimicrobial Agents and Chemotherapy New Orleans, LA, USA (1996):227 (Abstract J47).
   Google Scholar
• ELLIS M, SPENCE D, DE PAUVV B et al: An EORTC international multicenter randomized trial comparing 2 dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin. Infect. Dis. (1998) 27:1406–1412.
   PubMed Web of Science ®Google Scholar
• LORE T, BRAUN F, RUCHEL R et al: Systemic mycoses during prophylactical use of liposomal amphotericin B after liver transplantation. Mycoses (1999) 42:47.
   PubMedGoogle Scholar
• VARO E, TOME S, BUSTAMANTE M et al.: Fungal infection prophylaxis in high-risk liver recipients. 38th International Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, USA (1998) (Abstract J–138).
   Google Scholar
• SINGH N, PATERSON DL, GAYOWSKI T et al.: Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation (2001) 71:910–913.
   PubMedGoogle Scholar
• PALMER SM, DREW RH, WHITEHOUSE JD et al.: Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation (2001) 72:545–548.
   PubMed Web of Science ®Google Scholar
• PALMER SM, WHITEHOUSE J, DREW RH et al: Nebulized amphotericin B lipid complex prophylaxis is associated with a low reate of invasive fungal infections after lung transplantation. Am. I Resp. Crit. Care Med. (1998) 157:A330.
   Google Scholar
• CAGNONI PJ, WALSH TJ, PRENDERGAST MM et al: Pharmacoeconomic analysis of liposomal amphotericin B in the empirical treatment of persistently febrile neutropenic patients.Clin. Onto]. (2000) 18:3064.
   PubMedGoogle Scholar
• ENZON PHARMACEUTICALS: Collaborative Exchange of Antifungal Research Database.
   Google Scholar
• LARKIN JA, MONTERO JA: Efficacy andsafety of amphotericin B lipid complex for zygomycosis. Infect. Med. (2003) 20:201–206.
   Web of Science ®Google Scholar
• LEVINE SJ, WALSH TJ, MARTINEZ A et al: Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann. Intern. Med. (1991) 114:664–666.
   PubMed Web of Science ®Google Scholar
• GARNACHO-MONTERO J, ORTIZ-LEYBA C, GARCIA GARMENDIA JL et al.: Life threatening adverse event after amphotericin B lipid complex treatment in a patient treated previously with amphotericin B deoxycholate. Clin. Infect. Dis. (1998) 26:1016.
   Google Scholar
• RINGDEN 0, JONSSON V,HANSEN M et al.: Severe and common side effects of amphotericin B lipid complex. Bone Marrow Transplant. (1998) 22:733–734.
   Google Scholar
• ARNING M, HEER-SONDERHOFF AH, WEHMEIER A et al: Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia. Ear. I Clin. Microbial. Infect. Dis. (1995) 14:41–43.
   PubMedGoogle Scholar
• JOHNSON MD, DREW RH,PERFECT JR: Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. Pharmacothempy (1998) 18:1053–1061.
   PubMed Web of Science ®Google Scholar
• COLLAZOS J, MARTINEZ E, MAYO Jet al: Pulmonary reactions during treatment with amphotericin B: Review of published cases and guidelines for management. Clin. Infect. Dis. (2001) 33:e75-e82. 2109
   Google Scholar
• ROWLES DM, FRASER SL:Amphotericin B lipid complex associated hypertension: case report and review. Clin. Infect. Dis. (1999) 29:1564–1565.
   PubMed Web of Science ®Google Scholar
• EDWARDS JE, BODEY GP, BOWDEN RA et al.: International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin. Infect. Dis. (1997) 25:43–59.
   PubMed Web of Science ®Google Scholar
• STEVENS DA, KAN VL, JUDSON MA et al.: Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Societyof America. Clin. Infect. Dis. (2000) 30:696–709.
   PubMed Web of Science ®Google Scholar
• •Comprehensive evidence-based guidelines for the treatment and prevention of invasive aspergillosis in a variety of clinical settings. These guidelines however, were published prior to the release of both caspofungin and voriconazole.
   Google Scholar
• MORA-DUARTE J, BETTS R, ROTSDEIN C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl. J. Med. (2002) 347:2020–2029.
   PubMed Web of Science ®Google Scholar
• HERBRECHT R, DENNING DW, PATTERSON TF et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl. J. Med. (2002) 347:408–415.
   PubMed Web of Science ®Google Scholar